Oral agents for the management of gestational diabetes.

Erica K Berggren, Kim A Boggess

Journal: Clinical obstetrics and gynecology 2014;56(4):827-36

PMID: 24005130

Abstract

In gestational diabetes (GDM), achieving euglycemia through treatment decreases the risk of adverse outcomes associated with hyperglycemia. Treatment starts with diet and nutritional counseling; however, up to 50% of women will require pharmacologic therapy to meet glucose goals. Although insulin remains the only Federal Drug Administration-approved agent to treat GDM, oral hypoglycemic agents are an attractive and increasingly common alternative. Research suggests that glyburide and metformin can each effectively manage hyperglycemia in pregnancy. This review highlights research on efficacy, safety, and advantages versus disadvantages of each. We offer management and counseling strategies for clinicians caring for patients with GDM.

Address: *Department of Obstetrics and Gynecology, Thomas Jefferson University, Philadelphia, Pennsylvania †Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.